Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.

Undevia SD, Kindler HL, Janisch L, Olson SC, Schilsky RL, Vogelzang NJ, Kimmel KA, Macek TA, Ratain MJ. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.

View in: PubMed